Compare NWSA & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWSA | VTRS |
|---|---|---|
| Founded | 2012 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 14.2B |
| IPO Year | N/A | N/A |
| Metric | NWSA | VTRS |
|---|---|---|
| Price | $26.11 | $12.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 6 |
| Target Price | ★ $37.34 | $11.50 |
| AVG Volume (30 Days) | 3.7M | ★ 8.3M |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | 0.76% | ★ 3.83% |
| EPS Growth | ★ 230.83 | N/A |
| EPS | ★ 2.06 | N/A |
| Revenue | $8,500,000,000.00 | ★ $14,124,400,000.00 |
| Revenue This Year | $5.13 | N/A |
| Revenue Next Year | $3.30 | $1.18 |
| P/E Ratio | $12.82 | ★ N/A |
| Revenue Growth | ★ 2.20 | N/A |
| 52 Week Low | $23.38 | $6.85 |
| 52 Week High | $31.61 | $12.60 |
| Indicator | NWSA | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 77.01 |
| Support Level | $26.13 | $10.67 |
| Resistance Level | $26.50 | $12.49 |
| Average True Range (ATR) | 0.38 | 0.27 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 45.06 | 90.84 |
News Corporation is a diversified media conglomerate with large presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings business in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.